Leave Your Message
ADT1273-Gemtuzumab Biosimilar-Anti-CD33 mAb-Research Grade
Hot

ADT1273-Gemtuzumab Biosimilar-Anti-CD33 mAb-Research Grade

  • Catalog Number ADT1273
  • Host CHO Cells
  • Species Human
  • Target CD33
  • Application IF, IP, Neut, Functional assay, ELISA, FC, WB

CD33 (CD33 molecule) is a protein-encoding gene that can activate protein phosphatase binding activity, protein tyrosine phosphatase activator activity, and sialic acid binding activity. Participate in the regulation of immune response signaling pathways, negative regulation of cytokine production, and negative regulation of monocyte activation.

Alpha Lifetech provides pre-sales and after-sales services for our products, and our blocking antibody solutions will provide technical support for your research.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

CD33 or Siglec-3 (sialic acid binding immunoglobulin like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on myeloid cells. The extracellular portion of this receptor contains two immunoglobulin domains (one IgV domain and one IgC2 domain), making CD33 a member of the immunoglobulin superfamily.

Product Specification

Catalog Number

ADT1273

Product Name

ADT1273-Gemtuzumab Biosimilar-Anti-CD33 mAb-Research Grade

Alias

CDP-771, CMA-676 (ADC)

Isotype

IgG4 Kappa

Clonity

Monoclonal

Alternate Names

cd33 antibody, anti-cd33, mouse cd33, human cd33, anti cd33 antibody, anti cd33, anti cd33 monoclonal antibody, human cd33 antibody, recombinant cd33, anti-cd33 antibody, anti-cd33 monoclonal antibody, cd33 recombinant antibody, cd33 blocking antibody

Official Symbol

CD33

Species

Human

Expression Host

CHO Cells

Reactivity

Human

Gene ID

945

CAS Number

220578-59-6

Molecular Weight

151.50 KDa

Product Description

Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical. Eventually, cell death is induced.

Mechanism of Action

Gemtuzumab is a monoclonal antibody targeting CD33, a cell surface antigen expressed on leukemia cells.

Metabolism

Metabolic studies indicate hydrolytic release of the calicheamicin derivative from gemtuzumab ozogamicin. The drug is most likely removed by opsonization via the reticuloendothelial system.

Size

1mg,5mg

Research Area

Immunology

Application

IF, IP, Neut, Functional assay, ELISA, FC, WB

Purity

>95% as determined by SDS-PAGE

Concentration

Batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only. 

Reference

1. Sereshki N, et al. BMC Res Notes, 2023 Apr 20. PMID 37081561
2. Komuro R, et al. Cells, 2023 Feb 13. PMID 36831269
3. Castaño-Bonilla T, et al. Dis Markers, 2022. PMID 36051360

 

FAQ

Leave Your Message